After a finding of data manipulation, the corresponding author of a 2014 paper by a team of researchers at Indiana University has retracted the work.
Here’s the notice in Science Translational Medicine: Continue reading Indiana University paper about lung transplantation retracted after misconduct finding
In March 2017, a group of researchers in Vancouver, along with a colleague in Philadelphia, published a paper in the Proceedings of the National Academy of Sciences (PNAS) concluding that a particular antibiotic might be useful for treating conditions in people with rare mutations.
Then, this past July, while continuing the work, they had an unexpected result. That made them suspect that the antibiotic they thought they had ordered, gentamicin, wasn’t what they thought it was. With the help of a different company that sells the antibiotic, they confirmed they were studying a different compound — and retracted the paper.
Here’s the notice for “Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity:” Continue reading Researchers retract PNAS paper when they realize they’d been victims of an antibiotic switcheroo
In February of this year, the Joy of Cooking launched what you could call an epic Twitter stream. Inspired by Stephanie Lee’s reporting in BuzzFeed on Brian Wansink — the food marketing researcher at Cornell who later resigned following findings of misconduct by the university — the legendary cookbook pointed out all that was wrong with a 2009 study claiming that their recipes added calories over the years. Those tweets led to coverage in The Verge, The New Yorker, and elsewhere.
This week, the Annals of Internal Medicine retracted that paper, along with another. That brings Wansink’s tally of retracted papers to 17, with one of the papers retracted twice. (And no, 17 is nowhere near a record; he’s not even among the 30 authors with the most retractions in the world.) As Retraction Watch readers will likely recall, his work began to unravel when, after a 2016 blog post in which Wansink seemed to endorse p-hacking, four researchers joined forces to analyze his work.
Here’s the notice for 2009’s “The Joy of Cooking Too Much: 70 Years of Calorie Increases in Classic Recipes,” a paper that has been cited 20 times, according to Clarivate Analytics’ Web of Science: Continue reading The Joy of Cooking, vindicated: Journal retracts two more Brian Wansink papers
As we’re fond of repeating, sunlight is the best disinfectant. Which doesn’t jibe with the findings in an eye-catching 2018 paper that found people were less fearful of catching a contagious illness if they were in a dark room or were wearing sunglasses.
Fortunately for us, although not for the researchers, we no longer have to live with the cognitive dissonance. The paper, the journal tells us, will be retracted for flaws in the data — which, thanks to the open sharing of data, quickly came to light.
The study, which appeared in May in Psychological Science, reported that: Continue reading Psychology journal to retract study claiming that people fear contagion less in the dark
More than four and a half years after questions were first raised about work in a cardiac stem cell lab at Harvard and the Brigham and Women’s Hospital, a year and a half after the Brigham and Partners Healthcare paid $10 million to settle allegations of fraud in the lab’s data, a month after Harvard the Brigham disclosed that they were calling for the retractions of more than 30 papers from the lab, and three weeks after the NIH paused a clinical trial based on the work, two leading journals have issued an expression of concern about 15 papers from the lab.
But expressions of concern are not retractions, of course. From the notice, in Circulation and Circulation Research, both of which are published by the American Heart Association: Continue reading Journals stamp expressions of concern on 15 papers from Anversa’s cardiac stem cell lab
A professor at Kyung-Hee University in Seoul, South Korea, has retracted three articles and had at least ten corrected, all for image manipulation, duplication, or errors.
Joohun Ha’s three retractions all appeared in the Journal of Biological Chemistry (JBC). One of the papers, “AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells,” first published in 2003, has been cited 186 times, according to Clarivate Analytics’ Web of Science. Here’s the retraction notice: Continue reading Researcher in South Korea racks up three retractions and at least 10 corrections
Anil Jaiswal, who until a year ago was a cancer researcher at the University of Maryland, Baltimore, has had four more papers retracted.
That makes 21 for Jaiswal, who joins our leaderboard of the 30 researchers with the most retractions. All four new retractions appear in journals published by the American Association for Cancer Research, and are for image or data manipulation.
For example, here’s the retraction notice for “Aromatase Inhibitor–mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer,” in Molecular Cancer Therapeutics: Continue reading Former University of Maryland cancer researcher up to 21 retractions
In July 2017, a JAMA journal called for an investigation into a 2013 paper it had published after concluding that the article had “scientific and ethical concerns.” Now the journal, JAMA Otolaryngology − Head & Neck Surgery, is retracting the paper.
The article, “Dexamethasone for the prevention of recurrent laryngeal nerve palsy and other complications after thyroid surgery: a randomized double-blind placebo-controlled trial,” came from a group in Italy led by Mario Schietroma, of the Department of Surgery at the University of L’Aquila, in Abruzzo, Italy. Schietroma, who in December admitted to us that a retracted 2015 paper of his in the Journal of the American College of Surgeons suffered from “misinterpretation of the statistical data,” now has four retractions.
The paper has been cited a total of 18 times, according to Clarivate Analytics’ Web of Science, including twice since it was subjected to an expression of concern. One of those citations was by a Cochrane systematic review.
According to the retraction notice: Continue reading JAMA journal retracts paper when author can’t produce original data
The maker of a leading over-the-counter antacid has withdrawn its application for approval of the drug in China because a clinical trial of the product in that country was marred by “major protocol deviations.”
Researchers for the company, Reckitt Benckiser, maker of Gaviscon, had published a report on the study in 2015 in the journal Alimentary Pharmacology & Therapeutics. But the journal has now retracted the article, “Randomised clinical trial: The clinical efficacy and safety of an alginate‐antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China,” at the behest of the drug maker.
According to the notice: Continue reading “Sufficiently serious” issues in study prompt company to yank drug approval application in China
A researcher at the University of Kentucky who studies the cancer risks of toxic chemicals has retracted three papers.
All of the retraction notices, which appear in the Journal of Biological Chemistry, refer to some kind of image duplication. The papers were originally published between 2014 and 2017, with the 2014 paper cited 39 times, according to Clarivate Analytics’ Web of Science.